SBIR/STTR Research Award

An Isotonic Biome-Friendly Vaginal Moisturizer to Relieve Genitourinary Menopausal Symptoms

Award identifier 055f4347c4e9b4afaf49877dbc1b03233717eb51a066e6ce7f4ee327ec9dbf5fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,922

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
FAIRHAVEN HEALTH, L.L.C.
Proposal award date
2018-09-01
Contract end date
2019-02-28
UEI
Not reported
Solicitation number
PA17-302
Topic code
NICHD

Research abstract

An Isotonic Biome Friendly Vaginal Moisturizer to Relieve Genitourinary Menopausal Symptoms SUMMARYPostmenopausalPMwomen suffer from vaginal atrophywith a loss of natural moisture and elasticityas well as vaginal dysbiosis and increased vaginal pHcollectively known as the Genitourinary Syndrome of MenopauseGSMSymptoms of GSM include vaginal drynessburningirritation and malodoras well as sexual dysfunctionThere aremillion such women in the US and overof these women have signs of GSM at menopauseSymptoms progress over time and require continual treatmentCurrent vaginal lubricants and moisturizersVLandamp Mare first line therapies for GSM but they can cause vaginal mucosal damage and inhibit healthy lactobacillus growthbased on physiochemical properties and formula excipientsThere is an unmet need for a VLandamp M that relieves symptoms of GSM while minimizing disruption to the vaginal ecosystemThe overall goal of this proposal is to develop a biome friendlymoisturizinglubricating and pH balancing vaginal gel for improved GSM symptom relief in PM womenFairhaven Health specializes in womenandapos s healthincluding an isotonic vaginal product lineA VLandamp M gel prototype has been developedSAGEto improve GSM symptom relief by reducing immunemucosaland biome toxicitycompared to existing productsSAGEandapos s proprietary formula has been preliminarily found to cause less mucosal irritation and less disruption to healthy lactobacillus versus existing VLandamp MA novel unit dose applicator system has been designed to deliver the sterilepreservative free SAGEThe following PhaseAims will move SAGE towards commercializationAimFinalize Formula andampCompare Functional PropertiesAStudies will define the final SAGE formula and mixing protocols to ensure physiochemical properties are retained during sterilization and stability testingBStudies will confirm key functional propertiesfor GSM symptom reliefof mucoadhesionlubricity and buffering capacity of SAGE versus competitive productsAimVaginal Biome Compatibility Testing Evaluation of SAGE in this Aim will be performed by the Laboratory of Genital Tract Biology at Brigham and Womenandapos s HospitalAStudies will evaluate the impact of SAGE and competitive products on valuable vaginal Lactobacillus species of the healthy human vaginaBA human in vitro model study will monitor markers of cell damage and immunotoxicity following contact of bacteria colonized vaginal epithelia with SAGE versus competitive VLandamp MA final SAGE formula will be acceptable for a PhaseSBIR if it is equivalent or superior to other VLandamp M in functional propertiesand superior over competitors in epithelium associated lactobacillus colony forming unitsepithelial integrityand or markers of epithelial disruption and inflammatory activityThe team behind SAGE has combined expertise in clinical and experimental vaginal biologyvaginal product developmentregulatory clearancesterile manufacturing of gels and commercial sales in womenandapos s vaginal products An Isotonic Biome Friendly Vaginal Moisturizer to Relieve Genitourinary Menopausal Symptoms NARRATIVE Postmenopausal women suffer from vaginal atrophywith a loss of natural moisture and elasticityas well as a rise in vaginal pHcausing the Genitourinary Syndrome of MenopauseGSMwith symptoms of vaginal drynessburningirritation and malodoras well as sexual dysfunctionCurrent vaginal lubricants and moisturizersVLandamp Mare first line therapies for GSM but they can cause vaginal mucosal damage and harm healthy lactobacillusbased on their formulas and chemistryThe goal of this proposal is to develop a biome friendlymoisturizinglubricating and pH balancing vaginal gel for improved GSM symptom reliefusing a state of the art human invitro model to evaluate markers of cell damage and immunotoxicityas well as lactobacillus growth for the new gel versus existing VLandamp M

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.